Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115525913 | 11552591 | 3 | F | 20160808 | 20150925 | 20160810 | EXP | JP-ROCHE-1637682 | ROCHE | USUI K, SUGAWARA S, NISHITSUJI M, FUJITA Y, INOUE A, MOURI A, WATANABE H, SAKAI H, KINOSHITA I, OHHARA Y, MAEMONDO M, KAGAMU H, HAGIWARA K AND KOBAYASHI K. PHASE II STUDY OF BEVACIZUMAB WITH CARBOPLATIN-PEMETREXED IN NON-SQUAMOUS NON-SMALL CELL LUNG CARCINOMA PATIENTS WITH MALIGNANT PLEURAL EFFUSIONS: NORTH EAST JAPAN STUDY GROUP TRIAL NEJ013A. LUNG CANCER 2016;99:131-136. | 0.00 | Y | 0.00000 | 20160810 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115525913 | 11552591 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Unknown | DAY 1 (BOTH IN INDUCTION AND MAINTENANCE TREATMENT) | U | 125085 | 15 | MG/KG | Q3W | ||||||
| 115525913 | 11552591 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | U | 125085 | |||||||||||
| 115525913 | 11552591 | 3 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Unknown | AUC 6, ON DAY 1 (ONLY IN INDUCTION TREATMENT) | U | 0 | Q3W | ||||||||
| 115525913 | 11552591 | 4 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | U | 0 | |||||||||||
| 115525913 | 11552591 | 5 | SS | PEMETREXED | PEMETREXED | 1 | Unknown | DAY 1 (BOTH IN INDUCTION AND MAINTENANCE TREATMENT) | U | 0 | 500 | MG/M**2 | Q3W | ||||||
| 115525913 | 11552591 | 6 | SS | PEMETREXED | PEMETREXED | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 115525913 | 11552591 | 1 | Malignant pleural effusion |
| 115525913 | 11552591 | 2 | Non-small cell lung cancer |
| 115525913 | 11552591 | 3 | Malignant pleural effusion |
| 115525913 | 11552591 | 4 | Non-small cell lung cancer |
| 115525913 | 11552591 | 5 | Malignant pleural effusion |
| 115525913 | 11552591 | 6 | Non-small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 115525913 | 11552591 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 115525913 | 11552591 | Anaemia | |
| 115525913 | 11552591 | Decreased appetite | |
| 115525913 | 11552591 | Hypertension | |
| 115525913 | 11552591 | Infection | |
| 115525913 | 11552591 | Leukopenia | |
| 115525913 | 11552591 | Liver injury | |
| 115525913 | 11552591 | Neutropenia | |
| 115525913 | 11552591 | Proteinuria | |
| 115525913 | 11552591 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |